Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 1997

View Archived Issues

New agent for breast cancer in development at Zenyaku Kogyo

Oxygen carrier tested in patients with sickle cell disease

AmBisome approved in Russia

Fujisawa Foundation gives research grants

HemoCleanse submits 510(k) for ThermoChem-HT

R&D partnership announced between Helix BioPharma and PENCE

DiagnoCure granted U.S. patent for nanoerythrosomes

Patent for dry powder inhaler issued to TheraTech

CytoGam approved for marketing in Canada

Texas Biotechnology and SmithKline Beecham form marketing alliance for Novastan

IL-1ra tested for corneal transplant

YH-439 metabolites identified in rat urine

Labopharm: Q1 1997 highlights

Pain management: How to take control

DaunoXome approved in Russia

Genzyme Transgenics' cancer vaccine elicits immune response in myeloma patients

Results of RPR Gencell's gene therapy for Parkinson's disease reported

AVE seeks FDA approval for stent products

New analgesic/antiinflammatory compounds from Korea

First launch for new angiotensin II blocker

NMDA antagonist enters phase I for epilepsy

Atypical beta-adrenoceptor agonists from Glaxo Wellcome

Transkaryotic Therapies allowed European patent for gene therapy technology

Algos and NIDA enter into collaboration for heroin addiction treatment

Seragen grants U.S. Surgical option to restenosis product

Shionogi's beta-lactam antibiotic launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...